Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy

Pharmacogenomics

Volumn 12, Issue 12, 2011, Pages 1641-1652

  Giovannetti, Elisa ^a   Pacetti, Paola ^b   Reni, Michele ^c   Leon, Leticia G ^a   Mambrini, Andrea ^b   Vasile, Enrico ^d   Ghidini, Michele ^c   Funel, Niccola ^d   Lucchesi, Matteo ^d   Cereda, Stefano ^c   Peters, Godefridus J ^a   Cantore, Maurizio ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Piazza Sacco e Vanzetti   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d UNIVERSITY OF PISA   (Italy)

Author keywords

clinical outcome; pancreatic cancer; polychemotherapeutic regimens; polymorphisms; toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; ARGININE; ASPARAGINE; CAPECITABINE; CISPLATIN; DOCETAXEL; EPIRUBICIN; GEMCITABINE; GLUTAMINE;

AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DEATH; DIARRHEA; DNA POLYMORPHISM; DNA REPAIR; DRUG RESPONSE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HAND FOOT SYNDROME; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PREDICTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; WEAKNESS; XPD GENE; XRCC1 GENE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DNA REPAIR; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TAXOIDS; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 82255193117     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.109     Document Type: Article

References (53)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J. Clin. 60, 277-300 (2010).
2. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 363, 1049-1057 (2004). (Pubitemid 38410779)
3. Burris HA 3rd, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15, 2403-2413 (1997). (Pubitemid 27251144)
4. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat. Rev. Clin. Oncol. 7, 163-172 (2010).
5. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1960-1966 (2007). (Pubitemid 46972777)
6. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817-1825 (2011).
7. Reni M, Cordio S, Milandri C et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre Phase III trial. Lancet Oncol. 6, 369-376 (2005). (Pubitemid 40753742)
8. Reni M, Bonetto E, Cordio S et al. Quality of life assessment in advanced pancreatic adenocarcinoma: results from a PhaseIII randomized trial. Pancreatology 6, 454-463 (2006). (Pubitemid 44624279)
9. Reni M, Cereda S, Rognone A et al. A randomized Phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). Cancer Chemother. Pharmacol. doi:10.1007/s00280-011-1680-2 (2011) (Epub ahead of print).
10. Mambrini A, Pacetti P, Del Freo A et al. Gemcitabine-capecitabine plus intra-arterial epirubicin-cisplatin in pretreated pancreatic cancer patients: a Phase I study. Anticancer Res. 29, 1547-1549 (2009).
11. Giovannetti E, Del Tacca M, Mey V et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 66, 3928-3935 (2006).
12. Nakahira S, Nakamori S, Tsujie M et al. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int. J. Cancer 120, 1355-1363 (2007).
13. Nakano Y, Tanno S, Koizumi K et al. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br. J. Cancer 96, 457-463 (2007). (Pubitemid 46215217)
14. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Del Tacca M, Danesi R. Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol. Cancer Ther. 5, 1387-1395 (2006). (Pubitemid 44070474)
15. Kim MP, Gallick GE. Gemcitabine resistance in pancreatic cancer: picking the key players. Clin. Cancer Res. 14, 1284-1285 (2008). (Pubitemid 351413904)
16. Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 355, 983-991 (2006). (Pubitemid 44343542)
17. Danesi R, Pasqualetti G, Giovannetti E et al. Pharmacogenomics in non-small-cell lung cancer chemotherapy. Adv. Drug Deliv. Rev. 61, 408-417 (2009).
18. Tanaka M, Javle M, Dong X, Eng C, Abbruzzese JL, Li D. Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer 116, 5325-5335 (2010).
19. Okazaki T, Javle M, Tanaka M, Abbruzzese JL, LiD. Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin. Cancer Res. 16: 320-329 (2010).
20. Dong X, Jiao L, Li Y et al. Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. J. Clin. Oncol. 27, 1592-1599 (2009).
21. Chen J, Li D, Killary AM et al. Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation. Ann. Surg. Oncol. 16, 431-439 (2009).
22. Okazaki T, Jiao L, Chang P, Evans DB, AbbruzzeseJL, Li D. Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer. Clin. Cancer Res. 14, 2042-2048 (2008). (Pubitemid 351551114)
23. Li D, Liu H, Jiao L et al. Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival. Cancer Res. 66, 3323-3330 (2006).
24. Li D, Frazier M, Evans DB et al. Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. J. Clin. Oncol. 24, 1720-1728 (2006). (Pubitemid 46622144)
25. Ryu JS, Hong YC, Han HS et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44, 311-316 (2004).
26. Gurubhagavatula S, Liu G, Park S et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J. Clin. Oncol. 22, 2594-2601 (2004). (Pubitemid 41103746)
27. Wei SZ, Zhan P, Shi MQ et al. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med. Oncol. 28, 315-321 (2011).
28. Giovannetti E, Funel N, Peters GJ et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 70, 4528-4538 (2010).
29. Giovannetti E, Zucali PA, Peters GJ et al. Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. Mol. Cancer Ther. 9, 581-593 (2010).
30. Wacholder S, Chanock S, Garcia-Closas M, ElGhormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J. Natl Cancer Inst. 96, 434-442 (2004). (Pubitemid 38443646)
31. Heinemann V, Quietzsch D, Gieseler F et al. Randomized Phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J. Clin. Oncol. 24, 3946-3952 (2006). (Pubitemid 46630743)
32. Colucci G Labianca R, Di Costanzo F et al. Randomized Phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J. Clin. Oncol. 28, 1645-1651 (2010).
33. Peters GJ, van der Wilt CL, van Moorsel CJ, KroepJR, Bergman AM, Ackland SP. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol. Ther. 87, 227-253 (2000).
34. Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, BraakhuisBJ. Interaction between cisplatin and gemcitabine invitro and invivo. Semin. Oncol. 22 (4 Suppl. 11), 72-79 (1995).
35. Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ. Synergistic interaction between cisplatin and gemcitabine invitro. Clin. Cancer Res. 2, 521-530 (1996). (Pubitemid 26099172)
36. Lord RV, Brabender J, Gandara D et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 8, 2286-2291 (2002). (Pubitemid 34753602)
37. Park DJ, Zhang W, Stoehlmacher J et al. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin. Adv. Hematol. Oncol. 1, 162-166 (2003).
38. Stoehlmacher J, Park DJ, Zhang W et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br. J. Cancer 91, 344-354 (2004). (Pubitemid 39037082)
39. Viguier J, Boige V, Miquel C et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumour response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin. Cancer Res. 11, 6212-6217 (2005). (Pubitemid 41262950)
40. Isla D, Sarries C, Rosell R et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann. Oncol. 15, 1194-1203 (2004). (Pubitemid 39199306)
41. Allan JM, Smith AG, Wheatley K et al. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood 104, 3872-3877 (2004). (Pubitemid 39620132)
42. Gu J, Zhao H, Dinney CP et al. Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer. Clin. Cancer Res. 11, 1408-1415 (2005). (Pubitemid 40315220)
43. Chew HW, Doroshow JH, Frankel P et al. PhaseII studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J. Clin. Oncol. 13, 2163-2169 (2009).
44. Sissung TM, Danesi R, Price KM et al. Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol. Cancer Ther. 1, 19-26 (2008).
45. Park DJ, Stoehlmacher J, Zhang W, Tsao-WeiD, Groshen S, Lenz HJ. Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. Int. J. Colorectal Dis. 17, 46-49 (2002). (Pubitemid 41398991)
46. Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J. Clin. Oncol. 25, 4528-4535 (2007). (Pubitemid 350035308)
47. Stingl Kirchheiner JC, Brockmöller J. Why, when, and how should pharmacogenetics be applied in clinical studies?: current and future approaches to study designs. Clin. Pharmacol. Ther. 89, 198-209 (2011).
48. Lunn RM, Helzlsouer KJ, Parshad R et al. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis (Lond.) 21, 551-555 (2000). (Pubitemid 30214005)
49. Wei Q, Frazier ML, Levin B. DNA repair: a double-edged sword. J. Natl Cancer Inst. 92, 440-441 (2000). (Pubitemid 30182874)
50. McWilliams RR, Bamlet WR, CunninghamJM et al. Polymorphisms in DNA repair genes, smoking, and pancreatic adenocarcinoma risk. Cancer Res. 68, 4928-4935 (2008).
51. Duell EJ, Bracci PM, Moore JH, Burk RD, KelseyKT, Holly EA. Detecting pathway-based gene-gene and gene-environment interactions in pancreatic cancer. Cancer Epidemiol. Biomarkers Prev. 17, 1470-1479 (2008).
52. Tibaldi C, Giovannetti E, Vasile E et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. 14, 1797-1803 (2008). (Pubitemid 351469466)
53. Farrell JJ, Bae K, Wong J, Guha C, Dicker AP, Elsaleh H. Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer. RTOG 9704. Pharmacogenomics J. doi:10.1038/tpj.2011.22 (2011) (Epub ahead of print).